
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transfus Med Hemother</journal-id><journal-id journal-id-type="iso-abbrev">Transfus Med Hemother</journal-id><journal-id journal-id-type="publisher-id">TMH</journal-id><journal-title-group><journal-title>Transfusion Medicine and Hemotherapy</journal-title></journal-title-group><issn pub-type="ppub">1660-3796</issn><issn pub-type="epub">1660-3818</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH&#x02013;4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26696794</article-id><article-id pub-id-type="pmc">4678311</article-id><article-id pub-id-type="doi">10.1159/000441157</article-id><article-id pub-id-type="publisher-id">tmh-0042-0276</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Autoimmune Hemolytic Anemia - Fascinating from a Laboratory as well as from a Clinical Point of View</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heuft</surname><given-names>Hans-Gert</given-names></name><xref ref-type="aff" rid="aff1">a</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pru&#x000df;</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="aff2">b</xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Institute for Transfusion Medicine, Hannover Medical School, Hanover, Germany</aff><aff id="aff2"><sup>b</sup>Institute for Transfusion Medicine, Charite, Berlin, Germany</aff><author-notes><corresp id="cor1">*PD Dr. Hans-Gert Heuft, Institut f&#x000fc;r Transfusionsmedizin, Medizinische Hochschule Hannover, Carl-Neuberg-Stra&#x000df;e 1, 30625 Hannover, Germany, <email>Heuft.Hans-Gert@mh-hannover.de</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>27</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>9</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>42</volume><issue>5</issue><fpage>276</fpage><lpage>277</lpage><history><date date-type="received"><day>20</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>21</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 by S. Karger GmbH, Freiburg</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://www.karger.com/Authors_Choice"><license-p>This is an open access article distributed under the terms of Karger's Author's Choice&#x02122; licensing agreement, adapted from the Creative Commons Attribution Non-Commercial 2.5 license. This license allows authors to re-use their articles for educational and research purposes as long as the author and the journal are fully acknowledged.</license-p></license></permissions><counts><ref-count count="18"/><page-count count="2"/></counts></article-meta></front><body><p>Clinically the diagnosis of an autoimmune hemolytic anemia (AIHA) often starts with a patient with an unclear anemia, while in the laboratory the first hint is a blood sample with a positive direct antiglobulin test (DAT). Both anemia and positive DAT are non-specific findings that raise many questions. These include a wide range of laboratory characteristics such as immunoglobulin (sub-)class of the red blood cell (RBC) autoantibodies (Au-ab), presence of warm or cold Au-ab, thermal range of cold Au-ab, capability of Au-ab to activate complement, specificity of warm or cold Au-ab, and masking of additional RBC alloantibodies by Au-ab. Moreover, the clinical findings have to be scrutinized critically: Was there a sudden onset or a gradual beginning of hemolytic anemia? Is the hemolysis life-threatening? Does the patient suffer from a persisting systemic autoimmune or tumor disease, in particular a hematological malignancy? Has the patient been transfused within a certain time span before the first occurrence of the anemia symptoms? Was there a recent infection? Does the patient take drugs, newly or regularly?</p><p>If a clinician is confronted with a newly diagnosed AIHA, each of these questions has to be answered to distinguish &#x02018;idiopathic AIHA&#x02019; as a disorder of its own from &#x02018;secondary AIHA&#x02019; as a symptom of a detectable underlying disease (e.g. chronic lymphocytic leukemia, systemic lupus erythematosus, <italic>Mycoplasma pneumoniae</italic> infection). This classification is important for choosing the appropriate medical treatment of AIHA. In idiopathic AIHA that is present in about 45% of the AIHA cases [<xref rid="B1" ref-type="bibr">1</xref>] immunosuppressive drugs (corticosteroids and others) are most frequently applied to cope with severe hemolysis [<xref rid="B2" ref-type="bibr">2</xref>]. In secondary AIHA the &#x02018;drug of choice&#x02019; is governed by the underlying disease and may range from &#x02018;wait and see&#x02019; in self-limiting cases of infection-related AIHA, over immunosuppressive drugs in cases with an overt systemic autoimmune disorder to chemotherapy in patients with lymphoproliferative malignancies [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>]. Regardless of the clinical background, many AIHA patients have to be transfused, at least temporarily, as none of the available drugs are able to stop severe hemolysis immediately [<xref rid="B4" ref-type="bibr">4</xref>]. In view of these facts, each newly diagnosed &#x02018;AIHA&#x02019; may become a challenging experience for the doctor who is responsible for the patient for several reasons: i) There is no close relationship between the laboratory findings and the clinical symptoms of the patient. ii) Hypoxic anemia may require urgent transfusion. iii) A deliberate search for an underlying disease often leads to the somewhat dissatisfactory &#x02018;idiopathic&#x02019; AIHA. Moreover, none of the administered drugs - neither corticosteroids that are in routine use for decades nor newly introduced monoclonal antibodies such as rituximab - are always effective, and their beneficial immediate or long-term effects are not safely predictable [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>].</p><p>The present issue of <sc>Transfusion Medicine And Hemotherapy</sc> is an attempt to summarize and review theories, ideas, and medical expert knowledge on AIHA. John Freedman [<xref rid="B7" ref-type="bibr">7</xref>] and Wilma Barcellini [<xref rid="B8" ref-type="bibr">8</xref>] present the history of AIHA and discuss the current concepts that contribute to RBC destruction. Barcellini reports on the roles of cytokines and cytotoxicity effector cells (CD8+ T cells, natural killer cells, and activated macrophages) in the AIHA disease process, thereby explaining the great clinical heterogeneity of AIHA ranging from a fully compensated (&#x02018;uneventless') clinical course to rapidly evolving severe life-threatening hemolysis. The contributions of Sigbj&#x000f6;rn Berentsen [<xref rid="B9" ref-type="bibr">9</xref>] and Thilo Bartolm&#x000e4;s et al. [<xref rid="B10" ref-type="bibr">10</xref>] deal with the role of the complement system in the development of AIHA and describe the main mediators of complement-driven hemolysis, in particular in cold Au-ab-associated AIHA. Charles H. Packman [<xref rid="B11" ref-type="bibr">11</xref>] gives an overview on the clinical manifestations of AIHA while Beate Mayer et al. [<xref rid="B12" ref-type="bibr">12</xref>] present more than 70 cases with drug-induced hemolysis, mainly as a result of diclofenac, piperacillin and cephalosporin ingestion. Abdulgabar Salama [<xref rid="B13" ref-type="bibr">13</xref>] reviews pitfalls that may hamper the diagnose &#x02018;AIHA&#x02019; and summarizes his professional experience with the medical treatment of primary (&#x02018;idiopathic') AIHA over a period of 30 years. The latter contribution might provoke intense discussions among transfusion medicine specialists as the author attenuates the therapeutic enthusiasm with regard to newer drugs such as rituximab as the new &#x02018;gold standard&#x02019; for medical AIHA treatment.</p><p>When looking at the contents of this issue, you might wonder why one name seems to be nearly omnipresent in this special topic. It is not the task of this editorial to fully appreciate the tremendous scientific work of Abdulgabar Salama in the field of immunohematology over the last 30 years. However, as obvious for every specialist in transfusion medicine, Abdulgabar Salama has not only significantly influenced the field but has clearly dominated (together with his Californian colleague George Garratty) the diagnosis and the pathogenic background of drug-induced AIHA. His most important contribution is the discovery that many drugs supposed to be involved in severe AIHA are detectable in laboratory investigations only when their degradation products, either in serum/plasma or urine, are available (e.g. nomifensine [<xref rid="B7" ref-type="bibr">7</xref>], cephalosporin antibiotics such as ceftriaxone or cefotaxime [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>], or the non-steroid antirheumatic diclofenac [<xref rid="B10" ref-type="bibr">10</xref>], just to mention some frequently used medications). Another similarly important contribution to the understanding of the pathogenicity of AIHA is his observation that transfusion itself is able to induce Au-ab formation, often in coexistence with transfusion-associated alloantibody formation, thereby complicating a delayed serologic/hemolytic transfusion reaction [<xref rid="B11" ref-type="bibr">11</xref>]. These are only a few reasons why we are very glad to have allured such an exposed representative of AIHA research to significantly contribute to this special topic.</p></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelfried</surname><given-names>CP</given-names></name><name><surname>Overbeeke</surname><given-names>MA</given-names></name><name><surname>van dem Borne</surname><given-names>AE</given-names></name></person-group><article-title>Autoimmune hemolytic anemia</article-title><source>Semin Hematol</source><year>1992</year><volume>29</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">1570541</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanella</surname><given-names>A</given-names></name><name><surname>Barcellini</surname><given-names>W</given-names></name></person-group><article-title>Treatment of autoimmune hemolytic anemias</article-title><source>Haematologica</source><year>2014</year><volume>99</volume><fpage>1547</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">25271314</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Lechner</surname><given-names>K</given-names></name></person-group><article-title>Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review</article-title><source>Wien Klin Wochenschr</source><year>2008</year><volume>120</volume><fpage>136</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">18365153</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ness</surname><given-names>PM</given-names></name></person-group><article-title>How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situations?</article-title><source>Transfusion</source><year>2006</year><volume>46</volume><fpage>1859</fpage><lpage>1862</lpage><pub-id pub-id-type="pmid">17076838</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>KE</given-names></name><name><surname>Ness</surname><given-names>PM</given-names></name></person-group><article-title>Treatment of autoimmune hemolytic anemia</article-title><source>Semin Hematol</source><year>2005</year><volume>42</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">16041662</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>A</given-names></name></person-group><article-title>Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review</article-title><source>Transfus Med Hemother</source><year>2015</year><volume>42</volume><comment>DOI: 10.1159/000438731</comment></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>J</given-names></name></person-group><article-title>Autoimmune hemolysis: a journey through time</article-title><source>Transfus Med Hemother</source><year>2015</year><volume>42</volume><comment>DOI: 10.1159/000437195</comment></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barcellini</surname><given-names>W</given-names></name></person-group><article-title>New insights in the pathogenesis of autoimmune hemolytic anemia</article-title><source>Transfus Med Hemother</source><year>2015</year><volume>42</volume><comment>DOI: 10.1159/000439</comment></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berentsen</surname><given-names>S</given-names></name></person-group><article-title>Role of complement in autoimmune hemolytic anemia</article-title><source>Transfus Med Hemother</source><year>2015</year><volume>42</volume><comment>DOI: 10.1159/000438964</comment></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolom&#x000e4;s</surname><given-names>T</given-names></name><name><surname>Y&#x000fc;rek</surname><given-names>S</given-names></name><name><surname>Balola</surname><given-names>AHA</given-names></name><name><surname>Mayer</surname><given-names>B</given-names></name><name><surname>Salama</surname><given-names>A</given-names></name></person-group><article-title>Evidence suggesting complement activation and haemolysis at core temperature in patients with cold autoimmune haemolytic anaemia</article-title><source>Transfus Med Hemother</source><year>2015</year><volume>42</volume><comment>DOI: 10.1159/000437195</comment></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packman</surname><given-names>CH</given-names></name></person-group><article-title>Clinical pictures of autoimmune hemolytic anemia</article-title><source>Transfus Med Hemother</source><year>2015</year><volume>42</volume><comment>DOI: 10.1159/000440656</comment></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>B</given-names></name><name><surname>Bartolm&#x000e4;s</surname><given-names>T</given-names></name><name><surname>Y&#x000fc;rek</surname><given-names>S</given-names></name><name><surname>Salama</surname><given-names>A</given-names></name></person-group><article-title>Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre</article-title><source>Transfus Med Hemother</source><year>2015</year><volume>42</volume><comment>DOI: 10.1159/000440673</comment></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>A</given-names></name></person-group><article-title>Clinically and/or serologically misleading findings surrounding immune haemolytic anaemias</article-title><source>Transfus Med Hemother</source><year>2015</year><volume>42</volume><comment>DOI: 10.1159/000438960</comment></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>A</given-names></name><name><surname>Mueller-Eckhard</surname><given-names>C</given-names></name></person-group><article-title>The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia</article-title><source>N Engl J Med</source><year>1985</year><volume>313</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">4022080</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>O</given-names></name><name><surname>Hackstein</surname><given-names>H</given-names></name><name><surname>Hoppe</surname><given-names>B</given-names></name><name><surname>Goebel</surname><given-names>FJ</given-names></name><name><surname>Bein</surname><given-names>G</given-names></name><name><surname>Salama</surname><given-names>A</given-names></name></person-group><article-title>Fatal immune haemolysis due to a degradation product of ceftriaxone</article-title><source>Br J Haematol</source><year>1999</year><volume>105</volume><fpage>1084</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">10554824</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>A</given-names></name><name><surname>Gottsche</surname><given-names>B</given-names></name><name><surname>Schleiffer</surname><given-names>T</given-names></name><name><surname>Mueller-Eckhard</surname><given-names>C</given-names></name></person-group><article-title>Immune complex&#x02019; mediated intravascular hemolysis due to IgM cephalosporin-dependent antibody</article-title><source>Transfusion</source><year>1987</year><volume>27</volume><fpage>460</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">3500531</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>A</given-names></name><name><surname>Gottsche</surname><given-names>B</given-names></name><name><surname>Mueller-Eckhard</surname><given-names>C</given-names></name></person-group><article-title>Autoantibodies and drug- or metabolite-dependent antibodies in patients with diclofenac-induced immune haemolysis</article-title><source>Br J Haematol</source><year>1991</year><volume>77</volume><fpage>546</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">2025580</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahrens</surname><given-names>N</given-names></name><name><surname>Pruss</surname><given-names>A</given-names></name><name><surname>K&#x000e4;hne</surname><given-names>A</given-names></name><name><surname>Kiesewetter</surname><given-names>H</given-names></name><name><surname>Salama</surname><given-names>A</given-names></name></person-group><article-title>Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion</article-title><source>Transfusion</source><year>2007</year><volume>47</volume><fpage>813</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">17465945</pub-id></element-citation></ref></ref-list></back></article>